Enanta Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 82
- Registration Number
- NCT04196101
- Locations
- πΏπ¦
Clinical Projects Research SA pty Ltd, Worcester, Western Cape, South Africa
πΊπΈCentral Alabama Research, Birmingham, Alabama, United States
πΊπΈSaint Joseph's Clinical Research, Anaheim, California, United States
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 99
- Registration Number
- NCT04008004
- Locations
- πΊπΈ
University of Miami Miller School of Medicine, Miami, Florida, United States
πΊπΈAmerican Research Corporation, Houston, Texas, United States
π¨π¦Toronto General Hospital, Toronto, Ontario, Canada
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Oral Contraceptive
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT03783897
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
- Conditions
- RSV Infection
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT03755778
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03750383
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT03748628
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
- Conditions
- RSV Infection
- Interventions
- Drug: EDP-938 Dose 3Drug: PlaceboDrug: EDP-938 Dose 2Drug: EDP-938 Dose 4Drug: EDP-938 Dose 1
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 179
- Registration Number
- NCT03691623
- Locations
- π¬π§
hVIVO Services Limited (hVIVO), London, United Kingdom
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03610945
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- Drug: EDP-305 Dose 1Drug: EDP-305 Dose 2Drug: Placebo
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 134
- Registration Number
- NCT03421431
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈResearch Associates of South Florida, LLC, Miami, Florida, United States
π¨π¦Toronto Liver Centre, Toronto, Ontario, Canada
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: EDP-305 1 mgDrug: EDP-305 2.5 mgDrug: Placebo
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT03394924
- Locations
- πΊπΈ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
π§πͺUniversitair Ziekenhuis Gent, Gent, Oost-vlaanderen, Belgium
π³π±Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands